Myeloproliferative Disorders
"Myeloproliferative Disorders" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
| Descriptor ID |
D009196
|
| MeSH Number(s) |
C15.378.190.636
|
| Concept/Terms |
Myeloproliferative Disorders- Myeloproliferative Disorders
- Disorder, Myeloproliferative
- Disorders, Myeloproliferative
- Myeloproliferative Disorder
|
Below are MeSH descriptors whose meaning is more general than "Myeloproliferative Disorders".
Below are MeSH descriptors whose meaning is more specific than "Myeloproliferative Disorders".
This graph shows the total number of publications written about "Myeloproliferative Disorders" by people in this website by year, and whether "Myeloproliferative Disorders" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 3 | 1 | 4 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 4 | 1 | 5 |
| 2009 | 5 | 0 | 5 |
| 2010 | 2 | 0 | 2 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 3 | 0 | 3 |
| 2015 | 2 | 0 | 2 |
| 2016 | 3 | 1 | 4 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
| 2020 | 4 | 0 | 4 |
| 2021 | 1 | 1 | 2 |
| 2022 | 16 | 0 | 16 |
| 2023 | 14 | 0 | 14 |
| 2024 | 8 | 3 | 11 |
| 2025 | 10 | 0 | 10 |
| 2026 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myeloproliferative Disorders" by people in Profiles.
-
Menin-dependent megakaryocyte proliferation and fibrosis in myeloproliferative neoplasms. Cancer Cell. 2026 Aug 10; 44(8):1639-1652.e6.
-
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026. J Natl Compr Canc Netw. 2026 Jul; 24(7).
-
Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms. Blood Adv. 2026 05 26; 10(10):3746-3755.
-
Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms. Blood Adv. 2026 Mar 10; 10(5):1603-1613.
-
Contemporary data in myeloproliferative neoplasm-unclassifiable: mutational landscape and management of the 'unclassifiable'. Curr Opin Hematol. 2026 03 01; 33(2):45-50.
-
Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms. Blood. 2025 Aug 21; 146(8):971-983.
-
Germline predispositions to myeloid malignancies: Across the lifespan. Semin Hematol. 2025 06; 62(3):131-140.
-
Factors associated with survival after allogeneic transplantation for myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Jul 22; 9(14):3395-3407.
-
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT. Blood. 2025 May 29; 145(22):2561-2573.
-
Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases. Am J Hematol. 2025 06; 100(6):1010-1018.